Recent Finacing
Recent Raise
Mynvax develops engineered protein-subunit vaccines using protein‑stabilization technology to create heat‑tolerant formulations for influenza and SARS‑CoV‑2, pursuing clinical development and manufacturing partnerships.
Focus Areas
Recent Investors
Valuation as of 05/27/2024
Total Raised
Funding rounds
Investors
See the team members at Mynvax.
